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Successful stereotactic radiotherapy of meningiomas in a patient
with Cowden syndrome: a case report
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Abstract: Cowden’s Syndrome (CS) is a rare disease with increased risk for several carcinomas.
Experimental studies and limited case reports have described the negative effects of radiotherapy. A 35-yearold woman presented with newly diagnosed CS and multiple meningiomas. She underwent subtotal resection
of a right petroclival meningioma to relieve brainstem compression and received adjuvant fractionated
stereotactic radiotherapy 50 Gy in 25 fractions with minimal side effects. Twenty months post-operatively the
patient presented with neurological deficits from progression of additional meningiomas. Craniotomy was
performed and gross total resection was achieved for all sites of disease. Imaging five months after surgery
demonstrated progressive left tentorial meningioma. She underwent definitive stereotactic radiosurgery to
15 Gy and tolerated treatment well. At 32 and 7 months post-RT, the patient has reported no side effects or
toxicity as a result of RT, demonstrating for the first time in the literature, to the best of our knowledge, the
use of intracranial RT without significant toxicity in CS.
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Introduction
Cowden’s Syndrome (CS) is an autosomal dominant,
hereditary, and multisystem disease resulting in multiple
hamartomas throughout the body with an increased risk
of several carcinomas (1,2). It has incomplete penetrance
and variable expressivity with a germline mutation in
the phosphatase and tensin homolog (PTEN) tumor
suppressor gene on chromosome 10q23.3 (3,4). CS causes
an increased risk of breast, thyroid, endometrial, and renal
cell cancers with lifetime risk as high as 85%, 35%, 28%,
and 35%, respectively (5,6). Increased rate and number
of meningiomas in CS has been described in case reports.
However meningiomas do not fall under the syndrome’s
diagnostic criteria due to lack of data and high prevalence
in the general population (7,8). CS is rare with an estimated
prevalence of 1:200,000 patients; but this figure is likely an
underestimation due to under diagnosis (9).
There is a lack of evidence describing the effects of
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radiation as a treatment modality in this patient population.
Experimental studies have shown radiation sensitivity
following PTEN inhibition in cell lines (10). Limited case
reports have also described the negative effects of treating
CS patients with radiation therapy (RT) including secondary
malignancies, radiation dermatitis, and neurotoxicity
(10,11). Patients with CS and unresectable meningiomas
pose a conundrum: is RT safe in this population? We
present the following case of a 35-year-old woman with CS
and multiple meningiomas treated with multiple bouts of
RT in accordance with the CARE-Guideline (12).
Case presentation
A 35-year-old woman presented to our institution with a
recent diagnosis of CS and a magnetic resonance imaging
(MRI) of the brain was performed as part of her evaluation.
MRI demonstrated a lesion in the cerebellum suggesting
dysplastic gangliocytoma consistent with Lhermitte-
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Figure 1 Initial preoperative magnetic resonance imaging. Preoperative MRI of the brain T1 weighted post-gadolinium sequence with
representative axial planes of the left paraclinoid (A), left parafalcine and convexity (B), right petroclival with compression of the pons (C),
and right olfactory groove (D) meningiomas.

Duclos disease (LDD), considered part of CS, as well as
five intracranial, homogeneously enhancing masses of the
meninges consistent with meningiomas. The meningeal
lesions were left frontal parafalcine, left frontal convexity,
left paraclinoid, right petroclival, and right olfactory groove,
measuring 3.9, 3.4, 2.2, 3.3, and 0.4 cm in the longest
dimension, respectively (Figure 1). There was 1.6 cm
of brainstem compression in the region of the pons from
the petroclival lesion, and optic nerve abutment from the
paraclinoid mass. She was otherwise asymptomatic, and her
neurological exam was normal.
First treatment
The patient underwent a right middle fossa and
retrosigmoid craniotomy for resection of the right
petroclival meningioma. Subtotal resection (Simpson grade
IV) was achieved due to the fibrous nature of the lesion
and risk of cranial neuropathy. Pathology revealed lowgrade spindle cell processes, Ki-67 <1%, with positive
immunohistochemical stains for EMA and vimentin,
consistent with World Health Organization (WHO) grade
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I meningioma. Post-operative MRI of the brain showed
surgical changes with significant residual petroclival
disease and stability of the remaining meningiomas. Her
recovery was complicated by mild right sixth nerve palsy
and hoarseness which improved with follow-up. She was
referred to radiation oncology, and adjuvant RT was
recommended to the residual disease. Active surveillance
was elected for the remaining lesions as they were
asymptomatic, the patient did not want surgery, and concern
for malignant transformation from RT in the setting of CS.
The patient underwent fractionated stereotactic radiation
therapy (FSRT) 50 Gy in 25 fractions with a 2 mm
margin, prescribed to the 97% isodose line, using four
arcs and five modulated static beams (Figure 2). Mean dose
to the brainstem was 21.8 Gy, with maximal point dose
of 51.7 Gy. She completed adjuvant therapy four months
postoperatively with only grade 1 fatigue, headaches, and
nausea that self-resolved.
Follow-up brain MRI six months post adjuvant RT
showed interval decrease in the size of the right petroclival
meningioma from 2.4×3.0 to 1.9×1.8 cm2 with decreased
mass effect on the brainstem, and no evidence of brainstem
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Figure 2 Fractionated stereotactic radiotherapy plan. Radiation planning MRI of debulked right petroclival meningioma with representative
axial (A) and sagittal (B) slices. Prescription dose was 50 Gy in 2 Gy fractions to the 97% isodose line. Isodose lines represent 20, 30, 40, and
50 Gy doses, respectively.

edema. There was interval progression of the left frontal
parafalcine meningioma from 3.7×2.4 to 3.8×2.6 cm2 and
stability of the remaining three lesions. She continued to
be asymptomatic with no visual deficits. Surgical resection
was recommended due to progression. However, the patient
elected for continued surveillance.
Second treatment
At 18 months post-operatively the patient presented with
new onset of mild right arm weakness and headaches. MRI
at this time revealed progression of left parafalcine and
left frontal convexity meningiomas, significantly increased
cerebral edema, and increased mass effect with abutment of
the sagittal sinus. Surgical intervention for these two lesions,
the left clinoid, and right olfactory groove meningiomas was
recommended but was delayed due to patient preference.
Two months later the patient underwent image-guided
left frontotemporal craniotomy and achieved gross total
resection (Simpson Grade II) for all sites of disease. Postoperative MRI confirmed these changes as well as new small
meningiomas in the right anterior cranial fossa and left
tentorium, 3 and 5 mm respectively. Pathology of the left
frontal specimen was WHO grade II atypical meningioma
with brain invasion, reactive gliosis, and bone invasion with
KI67 of 2%, and the remaining lesions were WHO grade I.
The patient recovered without complication.
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MRI of the brain five months after surgery
demonstrated improvement in postoperative changes,
enlargement of the left tentorial meningioma, and
increased enhancement over the left frontal convexity
thought to be due to surgical changes. The patient
complained of occasional forgetfulness and fatigue but
was otherwise doing well. Review of prior radiation plan
did not reveal field overlap with new meningiomas, and
definitive RT was recommended to the progressing lesion.
She underwent stereotactic radiosurgery (SRS) to 15 Gy
using four stereodynamic arcs prescribed to the 81%
isodose line without margin, and minimal dose to critical
structures (Figure 3). Neurosurgery reported thorough
resection of the left frontal WHO grade II meningioma,
therefore observation was elected. The patient tolerated
treatment well and is currently being followed with
ongoing surveillance. Most recent MRI showed no
significant changes 32 months from original FSRT and
7 months post-SRS. She has reported no long term side
effects or toxicity as a result of her radiation treatments.
A timeline of care received by the patient is available in
Figure 4.
Discussion
There are few publications describing the use of
RT in patients with CS. One case report (abstract)
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Figure 3 Stereotactic radiosurgery plan. Radiation planning MRI of left tentorial meningioma with representative axial (A) and sagittal (B)
slices. Prescription dose was 15 Gy, single fraction to the 81% isodose line. Isodose lines represent 2, 5, 10, and 15 Gy doses, respectively.
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Figure 4 Timeline of Treatments. Timeline of care received by the patient including relevant radiographic imaging, surgeries, and
radiotherapies. MRI, magnetic resonance imaging; STR, subtotal resection; FSRT, fractionated stereotactic radiotherapy; GTR, gross total
resection; SRS, stereotactic radiosurgery.

describes the discontinuation of adjuvant radiation to
the breast due to severe skin desquamation (10). This
same patient experienced near total hair loss in the first
week of whole brain radiotherapy (WBRT) despite
the use of hippocampal sparing, intensity modulated
radiotherapy technique with the scalp receiving <10 Gy.
Four months after completing WBRT the patient developed
emesis, ataxia, and headache with MRI showing increased
intracranial edema and nodular enhancement believed to be
treatment-induced changes (10). In another report, a patient
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with CS was diagnosed with undifferentiated pleomorphic
sarcoma (UPS) of the breast, thought to be from adjuvant
RT for breast cancer seven years prior (11).
Our patient underwent multiple bouts of high dose,
definitive RT. However, unlike the case report by Tatebe et
al. our patient developed minimal toxicity or post-RT MRI
changes (10). There are several potential explanations for
the difference in outcomes. Firstly, we utilized stereotactic
techniques with minimal margins. Given the potential for
increased toxicity in this patient group, maximizing the
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therapeutic ratio is critical, reinforcing the principle of
“as low as reasonably achievable” (ALARA). The various
levels of penetrance and expressivity inherent to CS may
also provide explanation, with some patients possibly being
more sensitive to RT than others. In the case report by
Chandhanayingyong et al. they described the treatment
of a patient with CS and Ewing sarcoma of the pelvis.
The patient underwent neoadjuvant RT to 45 Gy prior to
hemipelvectomy with no significant toxicity reported (13).
There is no reliable way to identify patients that will develop
significant treatment toxicity. Indeed, given that our patient
had brain parenchymal manifestation of her disease via LDD,
it would have been reasonable to presume increased risk of
toxicity. Ultimately, the risk and benefits of RT should always
be considered and catered to each patient individually.
Due to limited evidence and few reports describing
these negative effects, RT has frequently been avoided in
CS patients. The reluctance to use radiation in CS patients
with intracranial disease leaves providers with limited
therapeutic options. When treating CS patients, non-RT
methods should be exhausted. If RT is necessary, highly
conformal, stereotactic techniques with minimal dose to
normal structures should be utilized to decrease potential
toxicity. Our case demonstrates the first successful use of
intracranial stereotactic RT in a CS patient. While more
evidence is needed, this offers a potential treatment option
for this patient population.
In conclusion, we report the first case, to the best of our
knowledge, of intracranial RT using stereotactic techniques
in a patient with CS who has not demonstrated significant
treatment toxicity to date. Previous reports of toxicity
may be due to the variable penetrance of the CS and large
RT fields used in prior reports. While RT has historically
been avoided in CS patients due to concern for secondary
malignancies and increased toxicity, consideration in select
patients utilizing stereotactic techniques may be viable after
exhaustion of non-RT interventions.
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